Usher syndrome type III (USH3) characterized by progressive loss of vision and hearing is caused by mutations in the clarin-1 gene (CLRN1). Clrn1 knockout (KO) mice develop hair cell defects by postnatal day 2 (P2) and are deaf by P21-P25. Early onset profound hearing loss in KO mice and lack of information about the cochlear cell type that requires Clrn1 expression pose challenges to therapeutic investigation. We generated KO mice harboring a transgene, TgAC1, consisting of Clrn1-UTR (Clrn1 cDNA including its 5′ and 3′ UTR) under the control of regulatory elements (Atoh1 3′ enhancer/β-globin basal promoter) to direct expression of Clrn1 in hair cells during development and down regulate it postnatally. The KO-TgAC1 mice displayed delayed onset progressive hearing loss associated with deterioration of the hair bundle structure, leading to the hypothesis that hair cell expression of Clrn1 is essential for postnatal preservation of hair cell structure and hearing. Consistent with that hypothesis, perinatal transfection of hair cells in KO-TgAC1 mice with a single injection of AAV-Clrn1-UTR vector showed correlative preservation of the hair bundle structure and hearing through adult life. Further, the efficacy of AAV-Clrn1 vector was significantly attenuated, revealing the potential importance of UTR in gene therapy.
Hereditary hearing loss (HHL) is a common sensory deficit often associated with hair cell defects1, and a good example of that is hearing loss linked to Usher syndrome (USH). USH is an autosomal recessive disorder and a common cause of combined deafness and blindness2. One subtype, USH3, is characterized by post-lingual, progressive hearing loss (PHL) and loss of vision with or without vestibular dysfunction3,4,5. The age of detection of hearing loss in USH3 subjects ranges from infancy to greater than 35 years, with most cases being diagnosed by the age of 10 years4,5. This provides an important therapeutic window before the onset of symptoms. However, lack of a progressive hearing loss model for USH3 has stymied progress in this regard.
USH3 is caused by mutations in the clarin-1 (CLRN1) gene, which encodes a four-transmembrane protein (CLRN1) closely related to tetraspanins6,7. CLRN1Y176X and CLRN1N48K are the most common mutations among USH3 cases4,6,7. Mouse knockout mutants generated to mimic nonsense (Clrn1KO/KO; referred to as “KO”) or missense (Clrn1N48K/N48K) mutations in humans are deaf by P258,9,10. Zebrafish clrn1KO/KO larvae are hearing impaired as well11. Hair cell mechanotransduction is attenuated in mice and zebrafish clarin-1 mutants8,10,11. Further, human CLRN1 protein, expressed in mouse or zebrafish hair cells, localizes to the hair bundle; whereas, human CLRN1N48K fails to reach the hair bundle and is largely retained in the endoplasmic reticulum10,11. Studies in clarin-1 mutant mice and zebrafish point to defects in the mechanosensory hair cells as the causative factor for inner ear dysfunction associated with clarin-1 mutation. The data discussed above strongly suggest clarin-1 is an essential hair cell protein across species.
The mechanosensory structure of the hair cell is the stereocilia (“hair”) bundle located on the apical surface of the cell. Deterioration of hair bundle morphology is observed as early as P2 in Clrn1 mutant mice10, making them a poor mammalian model to investigate postnatal therapeutic intervention, since treatment would have to be instituted prior to this damage. Additional challenges include lack of information regarding the cochlear cell type(s) that require Clrn1 expression and the timing of expression. Previous work showed that mouse Clrn1 mRNA is expressed constitutively in the inner ear (based on RT-PCR analysis), and mRNA in situ hybridization (ISH) of embryonic and neonate inner ear shows that Clrn1 is expressed in the spiral ganglion neurons (SGN) and hair cells (HCs)7,8.
The primary amino acid sequence of the clarin-1 protein (CLRN1) predicts 4-transmembrane domains similar to the tetraspanins family of membrane proteins7. Members of this family are considered structural proteins that interact laterally with other membrane proteins such as ion channels, integrins, and other tetraspanins to form tetraspanin-enriched microdomains12,13. Tetraspanins have been implicated in a variety of cellular functions, including regulation of cholesterol-dependent microdomains with actin cytoskeleton12,14. In vitro studies show that CLRN1 forms membranous cholesterol-rich compartments on plasma membranes, and it interacts with and regulates the machinery involved in actin filament organization15. Proteomics analyses revealed a number of clarin-1-interacting proteins involved in a variety of cellular function, including regulation of the actin cytoskeleton15. Harmonin, the Usher type IC gene product, interacts with many Usher proteins16,17,18. It is reported to interact directly with F-actin in vitro and stabilize F-actin when it is expressed in HeLa cells19. We propose that CLRN1 is necessary for maintenance of the F-actin core of the hair cell stereocilia and it mediates this function by interacting with other proteins involved in the regulation of actin cytoskeleton.
Based on clarin-1 literature discussed earlier, we predict that down regulation of CLRN1 expression in hair cells will result in the progressive disintegration of bundle structure and hearing loss; conversely, preservation of hearing in a clarin-1 mutant will require restoration of wild-type clarin-1 expression in hair cells in the mutant background. Here, we test our predictions and address several critical questions relating to the role of Clrn1 in USH3: (1) Is the expression of Clrn1 in SGNs and HCs necessary for the development of hearing, and is hearing (preservation) dependent on postnatal expression of Clrn1? (2) What is the consequence of postnatal down regulation of Clrn1 expression to hair cells? (3) Can a USH3 mouse model that displays delayed onset PHL be developed? (4) If so, is it possible to block or constrain PHL and prevent deafness in this model using viral gene therapy? (5) What is the importance of the untranslated region (UTR) of the Clrn1 mRNA with regard to gene therapy? Answers to these questions are critical to understanding the role of Clrn1 in the ear and in guiding future efforts to develop viable therapies for USH3 patients.
To address these questions, we generated KO mice carrying a transgene, TgAC1, that consisted of Clrn1-UTR (Clrn1 cDNA flanked by 5′ and 3′ UTR) under the control of regulatory elements (Atoh1 3′ enhancer/β-globin basal) known to direct expression of the target gene in hair cells during development and significantly down regulate it after birth (<P10)20. These mice are designated ‘KO-TgAC1’. We also designed AAV vectors that carry the coding sequence of Clrn1, with or without the UTR, and injected them in the ears of KO or KO-TgAC1 mice at postnatal day 2–3 (P2-P3). The KO-TgAC1 mice develop hearing, with ABR thresholds comparable to wild-type mice at a young age (P22), but fail to maintain that function over time. Our results suggests hair cell expression of Clrn1 is sufficient for hearing development, and postnatal hearing (preservation) is dependent on hair cell expression of Clrn1. Consistent with the latter observation perinatal administration of AAV-Clrn1-UTR vector blocks that progression of hearing loss in the new (KO-TgAC1) USH3 mouse model. The AAV based preservation of hearing in the new USH3 model (KO-TgAC1 mice) also provide proof of concept that gene therapy is effective in mitigating sensory deficit associated with CLRN1 mutation.
Conditional expression of Clrn1 in hair cells in the KO background
The scheme to generate and confirm the genotype of the transgenic mice is shown in Fig. 1. Mice homozygous for the KO allele (Clrn1KO/KO) and carrying the transgene are designated “KO-TgAC1” (Fig. 1). Atoh1 enhancer-mediated expression is detectable in mouse cochlear hair cells from embryonic stages to a week after birth20,21. The transgene (TgAC1) consists of the Clrn1 cDNA sequence with the UTR sequence fused downstream of the Atoh1 enhancer and β-globin basal promoter sequence (Fig. 1A). Translated and untranslated regions of the Clrn1 cDNA sequence included in the TgAC1 construct are depicted in Fig. 2.
The Atoh1 regulatory element (Atoh1 3′ enhancer/β-globin promoter/GFP) has been shown to be sufficient to direct expression of the target gene in hair cells of the organ of Corti during development and a few days after birth20,22. None of the antibodies to mouse CLRN1 tested was specific in immunohistochemistry. Therefore, we used alternate approaches to visualize control of the Atoh1 3′ regulatory enhancer in the organ of Corti. A mouse harboring an Atoh1-GFP transgene (Fig. 3A) served as a control to monitor conditional expression of the target protein in the organ of Corti. The GFP expression was robust in the inner hair cells (IHCs) and outer hair cells (OHCs) from the apex to the base of the cochlea at P1 but undetectable by P11 (Fig. 3B). The GFP expression data implies that, beyond P11, CLRN1 expression in cochlear hair cells of the TgAC1-KO mice will be significantly down regulated or absent after P11. The expression of Clrn1 mRNA in the cochlear duct sections from WT and KO-TgAC1 mice at P2 and P15 were examined by ISH. At P2, Clrn1 is expressed in IHCs and OHCs and the ganglion cells in the WT (Fig. 3C), consistent with earlier reports7,8. In the KO-TgAC1 mice, Clrn1 expression is restricted to the hair cells (Fig. 3C). At P15, Clrn1 expression persists in the WT hair cells but not in the KO-TgAC1 hair cells (Fig. 3C middle and bottom row). ISH results show temporal and spatial regulation of Clrn1 expression in the cochlea of KO-TgAC1 mice, and these results match expectations for gene expression under the control of the Atoh1 3′ enhancer element20,22. We hypothesized that postnatal down regulation of Clrn1 expression in the hair cells will result in progressive loss of hearing in mice.
KO-TgAC1 mice display delayed onset PHL
Hearing in the KO-TgAC1, KO and wild-type (WT) control mice, was monitored from P22 to P70 using auditory evoked brainstem response (ABR) thresholds at 8, 16 and 32 kHz (Fig. 4). The median ABR threshold in the WT mice was 30 ± 5 dB SPL. At P22, the KO mice showed profound hearing loss while most of the KO-TgAC1 mice had ABR thresholds closer to the WT mice at all frequencies tested. Over the next 40 days, hearing sensitivity in the KO-TgAC1 mice gradually decreased, reaching a state of profound hearing loss by P70 (ABR threshold >85–90 dB SPL). One-way ANOVA confirmed the statistical significance of these results (p ≤ 0.0001). Our results suggest: (1) hair cell expression of Clrn1 is necessary to develop hearing; (2) postnatal expression of Clrn1 in hair cells is necessary to maintain hearing after birth; and (3) compared to KO mice, the KO-TgAC1 mice display delayed onset progressive hearing loss.
Hair cell-specific expression of Clrn1 rescues core phenotype in the KO mice
To investigate the structural correlate associated with delayed onset progressive hearing loss in the KO-TgAC1 mice, hair bundle morphology was evaluated using field emission scanning electron microscopy (FESEM) of the mid-cochlear regions of WT, KO and KO-TgAC1 mice at P2, P10, P21, P36 and P100. At relatively low magnification, compared to WT mice, bundle morphology in all hair cells in KO mice was disrupted at all ages examined (Fig. 5A). The disarray was more prominent in the outer hair cells (OHCs) than in the inner hair cells (IHCs). Virtually all the OHC bundles appeared disturbed to some degree. In the KO-TgAC1 mice, the OHC and IHC bundles maintained relatively normal morphology (Fig. 5A). A higher magnification examination primarily of the OHC bundles was also undertaken. In contrast to the KO mice, the appearance of the bundle and shape of the cuticular plate in the KO-TgAC1 mice was grossly comparable to the WT mice from P2 to P36 (Fig. 5B). However, KO-TgAC1 mice begin to show signs of degeneration as early as P21; the shortest row of stereocilia became depleted to a greater extent than the age-matched WT mice (Fig. 5B). The IHC bundle morphology was similar in both the KO and KO-TgAC1 mice and showed loss of the shortest one to two rows of stereocilia with age. At P36, loss of the shortest row of stereocilia in the IHC is apparent (Fig. 5B). After P30, the bundle structure in IHCs and OHCs in the KO-TgAC1 mice deteriorated progressively over time, although disruption in bundle structure in the OHCs was readily identifiable or more prominent compared to IHCs. By P100, some ears had patches in which only a few OHC and IHC bundles remained, and these were severely disrupted (Fig. 5C). These studies show that the hair bundle phenotype in the KO-TgAC1 mice is consistent with the delayed onset, progressive hearing loss observed in this new model of USH3, suggesting that sustained postnatal expression of Clrn1 in hair cells is required to maintain hair bundle structure and hearing in adult mice.
AAV2 or AAV8 transfect cochlear hair cells in vivo
We next sought to determine whether viral-mediated gene therapy could prevent or further delay the onset of hearing loss in the KO-TgAC1 model. For these studies, constructs carrying the WT Clrn1 cDNA with or without the sequences representing the 5′ and 3′ UTRs were delivered to the cochlea of the KO-TgAC1 mice at P1-P3 using adeno-associated virus (AAV) serotype 2 or 8 through the round window membrane (RWM) as described previously23. To assess the extent of transfection of the organ of Corti by AAV, the WT mice were initially injected with AAV2-GFP and examined at P10. GFP was detected in almost all IHCs, whereas a mosaic pattern of expression was observed among the three rows of OHCs. Representative specimens from the mid-basal turn of the cochlea from two of the five mice injected with AAV2-GFP and AAV8-GFP are shown in Fig. 6A. As reported previously, AAV2 or AAV8 were much more effective at transfecting IHCs than OHCs23,24, though the precise reason behind this variable transfection in hair cells remains unknown.
AAV-Clrn1-UTR vectors constrain PHL in the KO-TgAC1 mice
AAV2 or AAV8 containing Clrn1 cDNA, with or without the UTR (Fig. 6B), were injected through the RWM of the KO or KO-TgAC1 mice at P1-P3, an age at which the hair cells in the KO-TgAC1 mice are comparable to those in the WT. In these mice, ABRs were recorded from 4 to 22 weeks after birth (P27 to P150) to monitor hearing preservation longitudinally. Seven KO-TgAC1 mice received AAV-Clrn1-UTR (KO-TgAC1-AAV-Clrn1-UTR) at P1-P3, and longitudinal ABR recordings were pursued until P150 (Fig. 6D). These mice showed sustained hearing preservation from the start (Fig. 6D). The suppression of progressive hearing loss by gene therapy is evident earlier on in the treated mice compared to the untreated (KO-TgAC1 subject to sham surgery) mice (n = 6, Fig. 6D). Starting at P70, the suppression was statistically significant for KO-TgAC1-AAV-Clrn1-UTR compared to KO-TgAC1 (Student’s t-test, p ≤ 0.02). However, the effect of gene therapy in KO-TgAC1 mice treated with AAV-Clrn1-UTR is outstanding starting at P90, when all other mice progress to profound hearing loss status (Fig. 6D). From P90 to P150, the mean difference in the ABR threshold between the KO-TgAC1 and KO-TgAC1-Clrn1-UTR was 38.3 dB SPL, which translates to improved hearing by more than three orders of magnitude. Our analysis shows that the threshold difference between the KO-TgAC1 and KO-TgAC1-Clrn1-UTR groups is statistically significant at 95% power (p < 0.01). In contrast, from P90 to P150, the mean difference in ABR threshold between KO-TgAC1 mice treated with AAV-Clrn1-without UTR (n = 10) and untreated KO-TgAC1 mice (n = 6) (Fig. 6D) is ≈5 dB SPL, and the difference is not statistically significant. These results demonstrate that AAV-mediated gene therapy can prevent deafness in the USH3 background, and AAV-Clrn1-UTR is the causal variant associated with the potent/stable therapeutic effect.
AAV-Clrn1-UTR vectors preserve the mechanosensory structure of hair cells
To determine the anatomical correlates of hearing preservation in KO-TgAC1 mice following AAV8-Clrn1-UTR injection, we compared hair bundle morphology from mice that displayed moderate hearing preservation (65 dB SPL ABR threshold) and good preservation (40 dB SPL ABR threshold) to WT mice at P100. The hair bundle morphology was significantly better preserved in the transfected KO-TgAC1 mice (Fig. 7) compared to the WT control (Fig. 7A,B). However, the integrity of the bundle morphology was commensurate with the degree of hearing preservation in the injected mice (Fig. 7C,D,E,F). Thus, the rescue of the hair cell bundle phenotype closely correlates with the rescue of hearing in the injected KO-TgAC1 mice. However, ABR thresholds did not reach normal threshold levels in injected KO-TgAC1 mice. We believe this is due to the variable transfection of OHCs, leading to variability in hearing thresholds. Nevertheless, these data demonstrate that virally mediated gene transfer can provide robust, long-term preservation of hearing in the delayed onset hearing loss model of USH3.
Immunolocalization of CLRN1-HA in IHCs and OHCs following AAV transfection
Immunolocalization of CLRN1 in the organ of Corti following AAV transfection would be ideal for the interpretation of the gene therapy data. However, specific labeling could not be obtained using the reported antibodies to the mouse CLRN125, or the antibodies generated by us to the mouse CLRN1 or to the zebrafish Clrn1 antibodies (Novus Biologicals). Alternatively, we used viral vectors carrying Clrn1 fused to HA (hemagglutinin) epitope (AAV8-mClrn1-HA). Immunolocalization using antibodies to HA epitope from independent specimens showed transfection of most IHCs and a mosaic pattern of transfection of OHCs in the three rows (Fig. 8A–D); cross sections revealed that hair cells, not supporting cells, express CLRN1-HA (Fig. 8C,D). Data shown in Fig. 8, combined with results described earlier (Figs 3C and 4), are consistent with the idea that hearing preservation in AAV-Clrn1 transfected TgAC1-KO mice is associated with hair cell expression of the target protein.
We generated a new USH3 mouse model that displays delayed-onset progressive hearing loss. To our knowledge, this is the first progressive hearing loss model for USH3. We developed this model by taking advantage of a proven regulatory element, the Atoh1 3′ enhancer20,21, to drive transient expression of Clrn1 in hair cells from the embryonic to perinatal stage and then down regulate after birth. We generated mice carrying the “Atoh1 enhancer-basal promoter-Clrn1 cDNA” transgene (TgAC1) in the KO background (KO-TgAC1). We hypothesized that the KO-TgAC1 mice would display delayed onset hearing loss, and the ensuing decrease in hearing sensitivity would be more gradual (relative to the phenotype evidenced by the KO mice), resulting in a progressive hearing loss model. ABR data (Fig. 4) were consistent with the hypothesis. Further, postnatal (P1-P3) transfection of hair cells in the KO-TgAC1 mice with a single injection of AAV-Clrn1-UTR vector showed preservation of the hair cell structure and hearing through adult life in the new model of USH3 (Fig. 6). Our results suggest that hair cell expression of Clrn1 is necessary for the development and postnatal preservation of hearing.
The viral gene therapy experiment involved 71 mice belonging to 7 groups tested longitudinally at various time points (Fig. 6D). To minimize variations in experimental and/or recording conditions, mice from the seven groups were processed (treated or untreated) and hearing evaluated within the same timeframe. To test hearing preservation, ABR thresholds to broadband click stimulus (as opposed to using pure tone stimuli) were recorded for two reasons. First, this method is adequate to address the important question namely, is it possible to block or slow down PHL in this model by viral gene therapy? If the PHL is constrained, we expect to keep deafness (total loss of hearing) at bay or delayed beyond P90, since the untreated KO-TgAC1 mice go deaf by P ≤ 90 (Fig. 6D). Second, we are working with a larger number (>20) of mice per recording session/time point (Fig. 6D) compared to characterization of PHL in the KO-TgAC1 model (10 per recording session/time point) (Fig. 4). Recording ABR thresholds to the click stimulus is quicker compared to recording ARB thresholds at multiple frequencies for each mouse. Our results (Fig. 6D) show that it is possible to constrain the progression of hearing loss and prevent early onset deafness in the KO-TgAC1 model via viral gene therapy. However, hearing thresholds in the AAV-Clrn1-UTR injected KO-TgAC1 mice were shy of the wild-type ABR threshold by 20–30 dB SPL. While variable transfection of outer hair cells by AAV vectors is a prime suspect, the long-term consequences of Clrn1 deficiency in the ganglion cells and the impact on hearing sensitivity require further investigation. We acknowledge that the ABR threshold response to broadband click stimuli is dominated by 4–16 kHz frequency responses with minimal contribution from the high frequency (>16 kHz) region of the mouse cochlea (example, Keller et al. 201126). Additional AAV gene transfer experiments are necessary to evaluate how well Clrn1 gene augmentation restores hearing in the KO-TgAC1 model in the 16–32 kHz region. Nevertheless, from P90 to P150, the mean difference in the ABR threshold between the KO-TgAC1 and KO-TgAC1-Clrn1-UTR mice translates to improved hearing by more than 1,000 times in the treated animals (Fig. 6D). These results provide proof of concept that gene augmentation could mitigate hearing loss in USH3 patients.
Immunolocalization of HA epitope expression in the IHCs and OHCs of the organ of Corti following AAV8-Clrn1-HA transfection (Fig. 8A–E) is consistent with the idea that hearing preservation in AAV-Clrn1 transfected TgAC1-KO mice is due to rescue of Clrn1 expression in hair cells. Additional experiments, namely ABR thresholds and immunofluorescence data from KO-TgAC1 mice transfected with AAV2- or AAV8-Clrn1-HA construct, are necessary to unequivocally demonstrate whether hearing preservation in AAV-Clrn1 transfected TgAC1-KO mice is due to rescue of Clrn1 expression in hair cells. The labeling pattern (Fig. 8B,C) is similar to the pattern observed with AAV2-GFP and AAV8-GFP (Fig. 6A), suggesting that AAV2 and AAV8 produce similar results in our hands. Though IHCs and OHCs were transfected by the AAV8-Clrn1-HA vector (Fig. 8A), the intensity of HA expression in hair cells appears to be lower and more variable between hair cells (Fig. 8B,C), compared to GFP signals in the AAV2-GFP or AAV8-GFP transfected organ of Corti (Fig. 6A). This difference is clear when GFP expression in the IHC rows in AAV2-GFP and AAV8-GFP (Fig. 6A) is compared to HA expression in the IHC row of AAV8-Clrn1-HA transfected cells (Fig. 8B,C). We believe the reduced/variable expression is due to lack of UTR of Clrn1 in the AAV8-Clrn1-HA construct. We surmise that Clrn1 UTR sequences increase stability of the transcript and efficiency of translation. Although these immunofluorescence images (Figs 6 and 8) were captured under similar settings, we note that our interpretations are not based on quantitative data. Rigorous quantitative analyses are required to test the hypothesis that Clrn1 UTR sequences increase stability of the transcript and efficiency of translation. We will test this hypothesis in future experiments.
Our results show that gene therapy is a promising approach to preserve hearing in USH3 patients. The results show that in KO-TgAC1 mice transfected with the Clrn1 coding sequence only, the rescue effect is barely perceptible or modest at best, whereas the inclusion of the UTR sequence improved hearing sensitivity by nearly four orders of magnitude in the KO-TgAC1 USH3 mouse model. In contrast, the KO mice injected with AAV2 or AAV8 -Clrn1-UTR demonstrated no hearing preservation (Fig. 6C). We suspect that lack of efficacy in the KO mice is because either AAV2 or AAV8 -Clrn1-UTR was injected after the onset of hair cell morphologic changes (P1-P3). This finding underscores the need to intervene with gene therapy prior to the onset of degeneration when treating a genetic defect that causes structural damage in the organ of Corti.
The results also emphasize that the UTR is critical for Clrn1 gene therapy. Interestingly, the Clrn1 3′ UTR sequence (2.1 kb) is 3 times longer than the coding sequence (<0.7 kb) and 12 times longer than the 5′ UTR (0.17 kb). The significance of this difference is unknown. However, reports in the literature suggest that the 3′ UTR increases stability of the transcript and efficiency of translation27. Although we cannot rule out an essential role for the 5′ UTR in Clrn1 gene rescue at this time, since the viral vector that rescued function in the KO-TgAC1 mice contains both 5′ and 3′ UTR (Fig. 6B), we strongly suspect that the 3′ UTR is critical for a robust gene rescue effect. We hypothesize that the 3′ UTR of Clrn1 plays a critical role in post-transcriptional regulation of gene expression, by modulating mRNA localization28,29,30, stability27, and/or translation31,32, as has been shown in other eukaryotic genes.
The strategies and findings reported here could assist the basic and translational investigation of HHL linked to other genes. Recent papers mark important milestones in gene therapy and add to advances toward treatment of HHL33,34,35,36,37,38,39. These advances have led to the restoration of inner ear function to varying degrees in mouse models of HHL. Our report sheds light on the limited therapeutic window for intervention in a conventional KO mouse model, and the need to consider untranslated sequence of the target gene in gene therapy. In mouse models of syndromic hearing loss, such as those associated with USH, hair cells show signs of degeneration (disrupted or missing stereocilia and/or missing hair cells) a few days after birth. Once cellular degeneration begins, it is likely that gene therapy will not reverse this process. The intervention must occur prior to the onset of degenerative events in the cochlea, which may explain why gene therapy efforts in the field have been largely restricted to treatment of neonate mice. In the USH KO models, we surmise that prenatal delivery or a strategy to delay the onset of degenerative events will be necessary to achieve robust hearing preservation. We show that gene therapy in the progressive (KO-TgAC1) hearing loss model for USH3 prevented deafness, but the same treatment did not prevent deafness in a conventional (KO) mutant model for USH3 (Fig. 6D). In addition, robust (~4 orders of magnitude better than controls) and sustained hearing preservation is aided by the presence of UTRs flanking the Clrn1 coding sequence; viral vectors carrying the Clrn1 coding sequence showed only some degree of hearing preservation early on, but it was not sustained (Fig. 6D). The strategy to delay the onset of hearing loss described in our report could help widen the postnatal therapeutic window in mouse models of HHL to gauge the efficacy of the gene therapy approach. We also believe that the inclusion of UTRs in gene therapy vectors will enhance the therapeutic outcome in other mouse models of HHL and other monogenic disorders in general.
In summary, virally mediated gene delivery in a mouse model of progressive hearing loss in USH3 can 1) effectively prevent the onset of deafness associated with a Clrn1 mutation and 2) deliver robust, long-term hearing preservation if the treatment is applied prior to the onset of the phenotype. Combined with early genetic diagnosis and family history, identifying USH3 individuals at-risk and intervening before they develop symptoms is a real possibility. Based on the results from our report and characteristics of USH3, we believe that clarin-1 is well suited for further development as a gene-therapy strategy to prevent deafness associated with USH3.
Materials and Methods
The transgenic mouse founder labeled TgAC1 (Transgene Atoh1-enhancer-Clrn1) was generated in the Case Transgenic and Targeting Facility under IACUC protocol number 2011–0094. The TgAC1 mice were bred with Clrn1 homozygous knockout mice (Clrn1KO/KO, labeled “KO”) to generate KO-TgAC1 mice. All protocols described in this report were approved by the Institutional Animal Care and Use Committee (IACUC) at Case Western Reserve University (CWRU) (protocol number 2010–0074 and 2013–0122) and at the University of California San Francisco (UCSF) (approval number AN098643–03). All procedures and animal handling complied with NIH ethics guidelines and approved protocol requirements of the IACUC at CWRU and UCSF. In this study, C57BL/6J mice were used as the wild type (WT) mice, and all the WT control material (DNA, RNA or protein) was obtained from this genetic background. All mice used in this study were maintained in the C57BL/6 J genetic background.
Generation of transgenic line KO-TgAC1
The aim was to generate Clrn1KO/KO that conditionally expresses the Clrn1 gene in hair cells from embryonic stages and down-regulate it postnatally. We generated a construct in which the Atoh1 enhancer (GenBank: AF218258) and β-globin basal promoter (nt 86 to 133 from human ß-globin gene; GenBank: KJ480748) fused to cDNA, representing a full-length transcript of mouse Clrn1, including 5′ and 3′ UTRs (GenBank:NM_153385.3). The Atoh1 enhancer element- ß-globin basal promoter construct was used previously to achieve hair cell specific expression of target genes20,21. Mice carrying the Transgene Atoh1-enhacer-Clrn-1 (TgAC1) were produced by pronuclear microinjection of TgAC1 into the WT male pronucleus of fertilized eggs from WT C57BL/6J mice (http://ko.cwru.edu/services/transgenics.shtml). The scheme to generate KO-TgAC1 mice is described later (Fig. 1).
A PCR-based protocol was used to identify the TgAC1 mice. Genomic DNA was isolated as described previously8. The primers used for genotyping were 5′-CCCTCTCTCACACCCCATTA-3′ (KA1109) and 5′-TGAGAACCGGAAAGGCCTTGC-3′ (KA1085). The expected size of the PCR product is 1,938 base pairs (bp). Clrn1 and Clrn1 knockout allele were identified as described previously8.
Preparation of recombinant AAV vectors
The mouse clarin-1 (Clrn1) cDNA with its 5′ and 3′ UTR sequences was 2,978 base pairs in length, and comprised a 5′ UTR (172 bp), the mouse Clrn1 coding sequence (699 bp), and a large 3′ downstream UTR (2107 bp) (GenBank Accession number: NM_153384.3; Fig. 2). A construct containing only the above 5′ and 3′ UTR sequences and a unique NotI site between them was synthesized by GenScript (Piscataway, NJ). This fragment containing flanking XhoI and BamHI restriction sites was directionally cloned into an AAV vector to generate a parent plasmid devoid of transgene. The Clrn1 coding sequence including 10 nucleotides 5′ proximal to the ATG start-codon was inserted via NotI in the above parent construct to generate “smCBA-Clrn1-UTR” plasmids. Transgene expression (Clrn1 or hGFP) is driven by the ubiquitous, constitutive smCBA (small chicken β-actin) promoter. The smCBA-Clrn1-UTR construct was separately packaged in the AAV2 or AAV8 capsid serotypes40. All vectors were produced, packaged, and purified according to previously reported methods40,41,42. Viral vector titers were determined by real-time PCR. Resulting titers for AAV2-smCBA-Clrn1-UTR (AAV2-Clrn1-UTR) and AAV8-smCBA-Clrn1-UTR (AAV8-Clrn1-UTR) were 8.60 × 1012 and 3.41 × 1013 vector genomes per milliliter (vg/mL), respectively.
Viral vector delivery
AAV2 or AAV8 were delivered to the KO-TgAC1 mice cochlea using the protocol described previously43. For gene therapy experiments, mice were injected at postnatal day 1–3 (P1-P3) for AAV2 or AAV8 vector delivery to the inner ear through the round window membrane (RWM). Auditory testing and cochlear histology were conducted at P21 and later. Mice were anesthetized either by hypothermia anesthesia (by placing them on ice for mice younger than P4), or by intraperitoneal injections of ketamine (100 mg/kg) and xylazine (10 mg/kg) (for older mice). Depth of anesthesia was continuously checked by deep tissue response to toe pinch. Body temperature was maintained with a heating pad and monitored with a rectal probe throughout the procedures. Animals were closely monitored for signs of distress and abnormal weight loss postoperatively. Mice of either sex were used.
Whole mouse cochlear epithelium for GFP imaging
Cochlear epithelium was dissected from P1 or P11 Atoh1-GFP mice and kept in cold phosphate buffered saline (PBS) for whole mount imaging. The protocol for processing and imaging was followed as described previously20.
Auditory-evoked brainstem response (ABR)
ABRs reflect the electrical responses of both the cochlear ganglion neurons and the nuclei of the central auditory pathway to sound stimulation40,41, and ABR thresholds refer to the lowest sound pressure level (SPL) that can generate these electrical responses. To evaluate hearing in KO-TgAC1 mice, we recorded ABR to pure tone frequencies, which represented the low (8 kHz), mid (16 kHz) and high (32 kHz) frequency ranges of the mouse cochlea. Since the Atoh1-enhancer is known to drive expression uniformly in all hair cells in the organ of Corti20,21, ABR from three characteristic frequencies along the tonotopic gradient of the cochlea should be representative of cochlear function in the KO-TgAC1 mice. Pure tone ABRs were recorded as previously described10.
Our goal is to determine whether a gene therapy approach can slow down, or prevent, the progression of hearing loss in the KO-TgAC1 model and, if so, whether that is a transient effect or whether that effect is sustained beyond the time point where untreated KO-TgAC1 mice normally become deaf (>P70). To determine the efficacy of gene therapy in the KO-TgAC1 mice following viral vector delivery (described later), ABR thresholds to broadband click stimuli were recorded. Thresholds to click stimulus reflect hearing function in the 4–16 kHz region of the mouse cochlea. Although a higher frequency region (16–32 kHz) of the mouse cochlea cannot be evaluated with confidence using the click stimulus, this approach is sufficient for the purposes stated above. Mice were anesthetized by an intraperitoneal injection of ketamine hydrochloride and xylazine hydrochloride as described previously42. After placing subdermal needle electrodes at the scalp vertex, below the pinna of the left ear and below the contralateral ear (ground), sounds were presented and ABRs were recorded in free-field conditions as previously described in a soundproofed chamber42,43. ABR thresholds were determined postoperatively at various time points, from 4 to 22 weeks after viral delivery. The lowest stimulus level that yielded a detectable ABR waveform was defined as the threshold, verified by visual inspection, with complementary computer analysis also defining ABR hearing thresholds for click stimuli.
Statistical methods used to analyze ABR data from KO-TgAC1 mice (Fig. 4): ABR threshold values of both left and right ears were averaged from each mouse belonging to wild-type (Clrn1+/+), KO (Clrn1KO/KO) and KO-TgAC1 (Clrn1KO/KO; TgAC1) mice at five time points (P22, P35, P46, P55 and P70) shown in Fig. 4, using Excel (Microsoft®, Redmond, VA). The mean ABR threshold from the groups at each time point were displayed as data points (color dot/symbol) with the standard error bars on a line graph (Fig. 4). One-way ANOVA analyses were used to determine whether the differences in ABR thresholds observed between the groups were significant. p values of <0.05 were considered statistically significant. One-way ANOVA analysis and line graphs were done using GraphPad software.
Power of sample size used for KO-TgAC1 and gene therapy treated groups (Fig. 6D): A power analysis was performed to determine whether the sample size used in the AAV viral mediated gene therapy experiment groups compared in each cohort was statistically significant (Fig. 6D). A power analysis to determine the effective sample size in each group was done as described previously44,45. Since no previous data is available for gene therapy experiments in a USH3 model, a priori power analysis for sample size calculation is not possible. Therefore, it was done posteriori with the outcome of this study. A post-hoc power analysis for sample size was carried out with the observed mean difference in the ABR threshold of 38 dB SPL from P90 to P150 between the untreated (sham surgery KO-TgAC1) and treated (KO-TgAC1 -AAV-Clrn1-UTR) groups using the G*Power 184.108.40.206 software45. From the power analysis, it was estimated that to achieve a 95% chance (power) of detecting >30 dB SPL mean difference in ABR threshold between groups, an ‘n’ of 5 is necessary for each group at time points after the onset of progressive hearing loss in the untreated (KO-TgAC1) group. A student’s t-test was done for the power of sample size, and a p-value of <0.01 was considered significant.
Scanning electron microscopy
Inner ears were excised from the head and fixed by intra-labyrinthine perfusion with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer containing 2 mM CaCl2. They were immersed in the fixative for 2 h and then stored in 1/10th fixative diluted with buffer until collected for further preparation. The samples were dissected in the buffer and immersed in 1% OsO4 in a sodium cacodylatre buffer for 1 h. Next, they were washed thoroughly and immersed in a saturated aqueous solution of sodium thiocarbohydrazide for 20 min. Again, they were washed thoroughly and immersed in 1% OsO4 in a sodium cacodylatre buffer for a further 2 h. The thiocarbohydrazide-osmium steps were repeated and the samples were then dehydrated in a graded series of ethanols, up to 100% ethanol dried over molecular sieve. They were placed in 100% dry ethanol in a critical point dryer, dried using liquid CO2 as the transitional fluid and mounted on stubs for insertion into an S4500 cold-field emission scanning electron microscope (FESEM) operated at 5 kV.
The procedure for viral micro-injection through the cochlear round window membrane (RWM) was performed on the neonatal mouse. Mice were anesthetized as previously described and a left post-auricular approach was used to expose the tympanic bulla. Subcutaneous tissue dissection with small scissors exposed the post-auricular muscle. After retracting the adipose tissue to the posterior side of the incision, the muscles were separated to the right and left side, perpendicular to the incision, to expose the otic bulla. The glass micropipette was inserted into the RWM through the soft otic bulla, avoiding the stapedial artery. A fixed volume of the viral vector [2 µl of AAV2-GFP (2.29 × 1012 vg/ml) or AAV8-GFP (2.13 × 1013 vg/ml) or AAV2-Clrn1-UTR (8.6 × 1012 vg/ml) or AAV8-Clrn1-UTR (3.4 × 1013 vg/ml)] previously drawn into the glass micropipette was gently injected through the RWM into the scala tympani over 1 min. To allow the vector to spread throughout the cochlear duct, the glass micropipette was left in place for ~1 min after the injection. Because the hole in the RWM was extremely small, leakage of perilymph was found to be insignificant after removing the micropipette. The incision was then sealed with connective tissue, and mice were kept in an isolated warm cage until they were fully recovered from anesthesia. They were then moved back with the mother.
Cochlear whole mount immunofluorescence
Mouse cochleae were perfused with 4% PFA in 0.1 M PBS (pH 7.4) and incubated in the fixative for 2hrs at 4 °C. The cochleae were subsequently rinsed with 0.1 M PBS three times for 10 min and then decalcified with 5% EDTA in 0.1 M PBS. The otic capsule, the lateral wall, the tectorial membrane, and Reissner’s membrane were removed in that order. The remaining organ of Corti was further dissected for a surface preparation (microdissected into individual turns), then pre-incubated for 1hr in the blocking buffer containing 0.25% Triton X-100 and 5% normal goat serum. For GFP labeling, the whole mount was then incubated with a rabbit anti-GFP antibody (Invitrogen A11122) diluted to 1:250 in 0.1 M PBS. After an overnight incubation at 4 °C, the cochlea turns were rinsed twice for 10 min with PBS and then incubated for 2hrs in goat anti-rabbit IgG conjugated to Cy2 (Jackson ImmunoResearch) diluted to 1:2000 in PBS.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This work was supported by the Usher III Initiative (K.N.A., L.R.L) and by funds from the Anthony J. Maniglia Endowed Chair, University Hospitals Case Medical Center and National Institutes of Health Grants R01-DC010816 and (K.N.A.). We would like to thank the Elden Family for their continuous support. We would like to acknowledge the following funding sources: Usher III Initiative, Inc., EY021721, Foundation Fighting Blindness, and Research to Prevent Blindness, Inc. We would like to thank Vince Chiodo, Sanford Boye and Santhi Mani for AAV vector cloning, production and purification.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.